Literature DB >> 14579141

Parathyroid hormone and its fragments in children with chronic renal failure.

Simon Waller1, Anthony Reynolds, Deborah Ridout, Tom Cantor, Ping Gao, Lesley Rees.   

Abstract

Parathyroid hormone (PTH) immunoradiometric assays (IRMA) exhibit cross-reactivity between 1-84 PTH and long carboxyl-terminal-PTH (C-PTH) molecules. C-PTH antagonizes the biological actions of 1-84 PTH and circulates in excess in chronic renal failure (CRF), partially explaining why supra-physiological PTH levels are recommended to maintain bone turnover. Furthermore, the ratio 1-84 PTH/C-PTH may be related to bone turnover. This study characterizes the 1-84 PTH/C-PTH ratio in children with varying severity of CRF and levels of PTH. Two hundred and forty-one children with CRF, managed with the aim of preventing the development of hyperparathyroidism, had PTH measured by 'intact' IRMA and a new more specific Cyclase-Activating-PTH (CAP) IRMA. C-PTH levels were calculated by subtracting CAP-IRMA from 'intact' IRMA. Fifty-three controls with normal renal function were also recruited. Mean 'intact' IRMA correlated with CAP-IRMA ( r=0.98), but was higher ( P<0.001). The mean 1-84 PTH/C-PTH ratio was lower than controls in dialysis patients ( P=0.022) and those with a glomerular filtration rate <30 ml/min per m(2 )( P=0.033). This ratio was comparable to controls when the PTH level was normal, but was lower with PTH levels outside the normal range ( P<0.01). These data suggest that CAP-IRMA gives a more accurate assessment of actual PTH levels than 'intact' IRMA in CRF. Maintenance of normal PTH levels throughout the course of CRF permits the maintenance of a normal 1-84 PTH/C-PTH ratio, the clinical significance of which requires further investigation in children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14579141     DOI: 10.1007/s00467-003-1267-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  33 in total

Review 1.  Prevention of metabolic bone disease in the pre-end-stage renal disease setting.

Authors:  J W Coburn; L Elangovan
Journal:  J Am Soc Nephrol       Date:  1998-12       Impact factor: 10.121

2.  The management of renal osteodystrophy.

Authors:  I B Salusky; W G Goodman
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

3.  Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells.

Authors:  P Divieti; N Inomata; K Chapin; R Singh; H Jüppner; F R Bringhurst
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

4.  High serum levels of a non-(1-84) parathyroid hormone (PTH) fragment in pediatric haemodialysis patients.

Authors:  R Salomon; M Charbit; M F Gagnadoux; P Niaudet; P Gao; T Cantor; J C Souberbielle
Journal:  Pediatr Nephrol       Date:  2001-12       Impact factor: 3.714

Review 5.  Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.

Authors:  S G Rostand; T B Drüeke
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

6.  A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure.

Authors:  M R John; W G Goodman; P Gao; T L Cantor; I B Salusky; H Jüppner
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

7.  Bone biopsy results and serum bone turnover parameters in uremic children.

Authors:  H Ziólkowska; M Pańiczyk-Tomaszewska; A Debiński; Z Polowiec; A Sawicki; M Sieniawska
Journal:  Acta Paediatr       Date:  2000-06       Impact factor: 2.299

8.  PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease.

Authors:  Giorgio Coen; Ermanno Bonucci; Paola Ballanti; Alessandro Balducci; Santo Calabria; Giulia A Nicolai; Maria Stephanie Fischer; Francesca Lifrieri; Micaela Manni; Massimo Morosetti; Eleonora Moscaritolo; Daniela Sardella
Journal:  Am J Kidney Dis       Date:  2002-08       Impact factor: 8.860

9.  Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease.

Authors:  A J Hutchison; R W Whitehouse; H F Boulton; J E Adams; E B Mawer; T J Freemont; R Gokal
Journal:  Kidney Int       Date:  1993-11       Impact factor: 10.612

10.  Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays.

Authors:  L Nguyen-Yamamoto; L Rousseau; J-H Brossard; R Lepage; P Gao; T Cantor; P D'Amour
Journal:  Eur J Endocrinol       Date:  2002-07       Impact factor: 6.664

View more
  8 in total

1.  Effect of haemodialysis on markers of bone turnover in children.

Authors:  Simon Waller; Deborah Ridout; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2007-01-10       Impact factor: 3.714

2.  Bone mineral content, corrected for height or bone area, measured by DXA is not reduced in children with chronic renal disease or in hypoparathyroidism.

Authors:  S Faisal Ahmed; Shiuli Russell; Rajeeb Rashid; T James Beattie; Anna V Murphy; Ian J Ramage; Heather Maxwell
Journal:  Pediatr Nephrol       Date:  2005-07-27       Impact factor: 3.714

3.  Comparison of 1-84 and intact parathyroid hormone assay in pediatric dialysis patients.

Authors:  Rita D Sheth; Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2005-04-23       Impact factor: 3.714

Review 4.  Parathyroid hormone and growth in chronic kidney disease.

Authors:  Simon Waller
Journal:  Pediatr Nephrol       Date:  2010-08-09       Impact factor: 3.714

5.  Differences between "intact" PTH and 1-84 PTH assays in chronic renal failure and dialysis.

Authors:  Simon Waller; Deborah Ridout; Tom Cantor; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2004-12-31       Impact factor: 3.714

Review 6.  New PTH assays and renal osteodystrophy.

Authors:  Isidro B Salusky; Harald Jüppner
Journal:  Pediatr Nephrol       Date:  2004-05-15       Impact factor: 3.714

7.  Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.

Authors:  G Klaus; A Watson; A Edefonti; M Fischbach; K Rönnholm; F Schaefer; E Simkova; C J Stefanidis; V Strazdins; J Vande Walle; C Schröder; A Zurowska; M Ekim
Journal:  Pediatr Nephrol       Date:  2005-10-25       Impact factor: 3.714

8.  What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence?

Authors:  Lesley Rees
Journal:  Pediatr Nephrol       Date:  2007-11-28       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.